Related posts
Bear market rally fadesStock slump continuesMideast tensions rattle Wall Street, oil and TSX climbThis summary was created by AI, based on 1 opinions in the last 12 months.
Humana Inc. has recently faced criticism from experts, particularly regarding its ability to price its products effectively. One review highlights the unfortunate timing for investors, noting a significant 11% drop in stock price on the day of the review. This suggests an alarming trend that could indicate deeper issues within the company's business strategies. Investors are urged to be cautious as a company's pricing power is a crucial factor for long-term success. The general sentiment appears to be that without proper pricing strategies, Humana may struggle to maintain investor confidence and achieve sustainable growth.
The markets has this wrong. They reported last week then shares tumbled more than 6% in a strong market week. He's taken profits on this but still owns many shares. Is beating the S&P since June. HUM actually reported a good quarter: strong earnings beat, 6% up YOY, sales up 18%. But shares came up way too high leading up to that report, so high expectations. Their benefits expense ratio came in lower than expected (good), but the core insurance segment ratio's was higher than expected. Also, their forecast suggests this ratio could go higher, due to a wave of Covid cases that hit sooner than they expected. Wall St. didn't like that HUM did not upgrade their full-year guidance. HUM projected slower, but more profitable growth. Run by good managers. Own for the long term.
Humana has gone from $420 to $500 in the past month. Healthcare stocks are climbing, but he prefers HC insurance than the drug companies, because their earnings are more predictable and trade a lot cheaper. 42% of Americans are obesity, so there's a lot of potential demand for these new, popular diet drugs. However, a lot of these people are also insured. Remember that the drugs space is competitive and eventually new drugs go generic. Insurance doesn't suffer that problem, and there isn't much variability in their earnings (they're more predictable). He also likes UNH.
They serve 17 million benefits plan members, focusing on Medicare, the fastest-growing segment in US healthcare. Boasts 20% return on shareholder equity, growing earnings at 14% compounded over the past decade. This should continue, given demographics and inflation. Also, in a non-cyclical part of the market in coming quarters. Pullback allows a good entry point.
(Analysts’ price target is $597.91)Humana Inc is a American stock, trading under the symbol HUM-N on the New York Stock Exchange (HUM). It is usually referred to as NYSE:HUM or HUM-N
In the last year, 1 stock analyst published opinions about HUM-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Humana Inc.
Humana Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Humana Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Humana Inc In the last year. It is a trending stock that is worth watching.
On 2025-04-14, Humana Inc (HUM-N) stock closed at a price of $284.82.
He was lucky to get out of this before today's 11% slide. If you can't price your products, get out of the business.